Experienced in Autosomal Dominant Hypocalcemia

Erik F. Eriksen

Pilestredet Park Specialist Centre And Faculty Of Odontology, 
Oslo, NO 
Experienced in Autosomal Dominant Hypocalcemia
Pilestredet Park Specialist Centre And Faculty Of Odontology, 
Oslo, NO 
OverviewLocationsClinical Research

Overview

Erik Eriksen practices in Oslo, Norway. Mr. Eriksen is rated as an Experienced expert by MediFind in the treatment of Autosomal Dominant Hypocalcemia. His top areas of expertise are Osteoporosis, Hypoparathyroidism, Postmenopausal Osteoporosis, Hormone Replacement Therapy (HRT), and Gastric Bypass.

His clinical research consists of co-authoring 103 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Autosomal Dominant Hypocalcemia.

Gender
Male

Locations

Pilestredet Park Specialist Centre And Faculty Of Odontology, Oslo, Norway
Other Locations
Bergen, Norway
Blindern, 1142, Norway
Nydalen, 0424, Norway
Aker, Norway

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

PARADIGHM (Physicians Advancing Disease Knowledge in Hypoparathyroidism): A Registry for Patients With Chronic Hypoparathyroidism
PARADIGHM (Physicians Advancing Disease Knowledge in Hypoparathyroidism): A Registry for Patients With Chronic Hypoparathyroidism
Enrollment Status: Active_not_recruiting
Publish Date: September 29, 2025
Intervention Type: Other
Zoledronic Acid as Adjuvant Therapy in Neovascular Age-related Macular Degeneration (The Z-AMD Study): A Randomized Controlled Pilot Study
Zoledronic Acid as Adjuvant Therapy in Neovascular Age-related Macular Degeneration (The Z-AMD Study): A Randomized Controlled Pilot Study
Enrollment Status: Completed
Publish Date: April 05, 2024
Intervention Type: Drug
Study Drug: Zoledronic Acid
Study Phase: Phase 2
View 1 Less Clinical Trial

103 Total Publications

Management of aromatase inhibitor-associated bone loss (AIBL) in women with hormone-sensitive breast cancer: An updated joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG.
Management of aromatase inhibitor-associated bone loss (AIBL) in women with hormone-sensitive breast cancer: An updated joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG.
Journal: Journal of bone oncology
Published: April 09, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Eriksen's expertise for a condition
ConditionClose
    View All 24 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile